Model for predicting the severity and outcome of COVID-19 in patients with diabetes mellitus and obesity created based on artificial intelligence methods
- Authors: Aramisova L.S.1, Zhurtova I.B.1, Akhubekova Z.A.1
-
Affiliations:
- Berbekov Kabardino-Balkarian State University
- Issue: Vol 31, No 8 (2024)
- Pages: 84-90
- Section: Original articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/680236
- DOI: https://doi.org/10.18565/pharmateca.2024.8.84-90
- ID: 680236
Cite item
Abstract
Background. According to WHO, type 2 diabetes mellitus and obesity are non-communicable epidemics of the 21st century. At the end of 2020, the world community expected the development of the COVID-19 pandemic, which became an epidemic of infectious genesis. Currently, there is a need to identify risk factors for severe course and high mortality in one of the most vulnerable groups of the population with metabolic disorders (DM and obesity) in order to improve the prognosis of COVID-19.
Objective. Development of the model for predicting the severity and outcome of COVID-19 in patients with diabetes mellitus and obesity to optimize diagnostic/treatment tactics.
Methods. The study was conducted in two directions: a retrospective analysis and a prospective part. The retrospective analysis included 645 patients with COVID-19 (58.6% women, 41.4% men). The mean age of patients was 63.6 ± 0.9 years. Diabetes mellitus and obesity occurred in 48.8% (n = 315) and 45.5% (n = 290) of cases, respectively. To identify the features of the clinical course and predictors of an unfavorable prognosis of COVID-19, all patients were divided into 2 groups: group 1 – with recovery (n = 443), group 2 – with an unfavorable outcome (n = 202), between which a comparative analysis was carried out. To develop a prediction model using artificial intelligence (AI) methods, several types of machine learning (ML) algorithms were implemented, among which logistic regression was selected. Regression analysis allowed to classify patients into 2 groups. Class 0 – no risk of adverse outcome and class 1 – high risk of adverse outcome. The prospective part included 130 patients, who formed the validation sample for our study. All patients were distributed according to the severity of COVID-19; demographic, clinical, anamnestic, laboratory and instrumental data from archival medical records were assessed.
Results. The analysis was carried out using 4 main ML algorithms: logistic regression, random forest, support vector machine, gradient boosting. The logistic regression model was chosen for further use in this task, since it showed the highest results for all key metrics, including accuracy, recall and ROC-AUC. The set of basic parameters were represented by the following features: gender, age, day from the onset of the disease, anthropometric data (body weight, height) based on which the body mass index (BMI) is automatically calculated, concomitant diseases (DM, coronary artery disease, arterial hypertension, chronic kidney disease, chronic obstructive pulmonary disease, bronchial asthma), medications taken (insulin therapy, oral hypoglycemic agents, glucocorticosteroids) and laboratory parameters (glucose, creatinine, cholesterol, uric acid, interleukin-6, leukocytes, D-dimmer, total protein, creatinine, urea, aspartate aminotransferase, prothrombin index, C-reactive protein levels) and respiratory function parameters (chest MSCT, respiratory rate, SpO2). Based on the introduction of these data, the model predicted the probable outcome (favorable/unfavorable). After validation in the prospective part of the study, our AI model predicted the risk of an unfavorable outcome with a probability of 96%.
Conclusion. The developed prognostic model allows to prevent the unfavorable course of COVID-19 by timely assessing the severity of the condition and optimizing treatment tactics in the most vulnerable group of patients with metabolic disorders.
Full Text

About the authors
L. S. Aramisova
Berbekov Kabardino-Balkarian State University
Author for correspondence.
Email: liaramisova@gmail.com
ORCID iD: 0000-0001-8105-4235
Postgraduate Student at the Department of Faculty Therapy of the Medical Academy
Russian Federation, NalchikI. B. Zhurtova
Berbekov Kabardino-Balkarian State University
Email: liaramisova@gmail.com
ORCID iD: 0000-0003-0668-1073
Russian Federation, Nalchik
Z. A. Akhubekova
Berbekov Kabardino-Balkarian State University
Email: liaramisova@gmail.com
ORCID iD: 0009-0008-9356-5655
Russian Federation, Nalchik
References
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/.
- Poorolajal J. The global pandemics are getting more frequent and severe. J Res Health Sci. 2021;21(1):e00502. doi: 10.34172/jrhs.2021.40.
- Stefan N/, Sippel K/, Heni M/, et al. Obesity and Impaired Metabolic Health Increase Risk of COVID-19-Related Mortality in Young and Middle-Aged Adults to the Level Observed in Older People: The LEOSS Registry. Front Med (Lausanne). 2022;9:875430. doi: 10.3389/fmed.2022.875430.
- Floyd J.S., Walker R.L., Kuntz J.L., et al. Association Between Diabetes Severity and Risks of COVID-19 Infection and Outcomes. J Gen Intern Med. 2023;38(6):1484–92. doi: 10.1007/s11606-023-08076-9.
- Li Y., Ashcroft T., Chung A., et al. Risk factors for poor outcomes in hospitalised COVID-19 patients: A systematic review and meta-analysis. J Glob Health. 2021;11:10001. doi: 10.7189/jogh.11.10001.
- Gattinoni L., Chiumello D., Caironi P., et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099–102.
- Арамисова Л.С., Журтова И.Б., Губачикова А.М. Сахарный диабет и новая короновирусная инфекция: взгляд в прошлое, выводы на будущее по профилактике и лечебной тактике. Фарматека. 2023;30(12):27–31. [Aramisova L.S., Zhurtova I.B., Gubachikova A.M. Diabetes mellitus and new coronavirus infection: a look into the past, conclusions on prevention and treatment tactics for the future. 2023;30(12):27–31. (In Russ.)]. doi: 10.18565/pharmateca.2023.12.27-31.
- Mesinovic M., Wong X.C., Rajahram G.S., et al. ISARIC Characterisation Group. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods. Sci Rep. 2024;14(1):16387. doi: 10.1038/s41598-024-63212-7.
- Xie J., et al. Development and external validation of a prognostic multivariable model on admission for hospitalized patients with covid-19. 2020.
- Alaa A., Qian Z., Rashbass J., et al. Retrospective cohort study of admission timing and mortality following covid-19 infection in England. BMJ. Open. 2020;10:e042712. doi: 10.1136/bmjopen-2020-042712.
- Knight S.R., Gupta R.K., Ho A., et al. Prospective validation of the 4c prognostic models for adults hospitalised with covid-19 using the isaric who clinical characterisation protocol. Thorax. 2021;77:606–15. doi: 10.1136/thoraxjnl-2021-217629.
- Jones A., Pitre T., Junek M., et al. External validation of the 4c mortality score among covid-19 patients admitted to hospital in Ontario, Canada: A retrospective study. Sci Rep. 2021;11:1–7. doi: 10.1038/s41598-021-97332-1.
- Baqui P., Marra V., Alaa A.M., et al. Comparing covid-19 risk factors in brazil using machine learning: The importance of socioeconomic, demographic and structural factors. Sci Rep. 2021;11:1–10. doi: 10.1038/s41598-021-95004-8.
- Fauci A.S., Lane H.C., Redfield R.R. Covid-19 – navigating the uncharted. N Engl J Med. 2020;382:1268–9. doi: 10.1056/NEJMe2002387.
- Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. и др. Международный регистр «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS COV-2 (AКТИВ SARS-COV-2)»: анализ 1000 пациентов. Российский кардиологический журнал. 2020;25(11):98–107. [Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G., et al. International registry «Analysis of the dynamics of comorbid diseases in patients infected with SARS COV-2 (ACTIVE SARS-COV-2)»: analysis of 1000 patients. Russian journal of cardiology. 2020; 25 (11): 98–107. (In Russ.)]. doi: 10.15829/1560-4071-2020 4165.
- Горошко Н.В., Пацала С.В. Основные причины избыточной смертности населения в России в условиях пандемии COVID-19. Социальные аспекты здоровья населения. 2021;67(6). [Goroshko N.V., Patsala S.V. The main causes of excess mortality in Russia during the COVID-19 pandemic. Social’nye aspekty zdorov’a naselenia. 2021;67(6). (In Russ.)]. doi: 10.21045/2071-5021 2021-67-6-1.
- Floyd J.S., Walker R.L., Kuntz J.L., et al. Association between diabetes severity and risks of COVID-19 infection and outcomes. J Gen Intern Med. 2023;38(6):1484–92. doi: 10.1007/s11606-023-08076-9.
- Kastora S., Patel M., Carter B., et al. Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: an umbrella systematic review and meta-analysis. Endocrinol Diab Metab. 2022;5(3):e00338. doi: 10.1002/edm2.338.
- Dessie Z.G., Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC. Inf Dis. 2021;21(1):855. doi: 10.1186/s12879-021-06536-3.
- Peckham H., de Gruijter N.M., Raine C., et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11:6317. doi: 10.1038/s41467-020-19741-6.
- Booth A., Reed A.B., Ponzo S., et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLOS ONE. 2021;16(3):e0247461. Doi: https://doi.org/10.1371/journal.pone.0247461.
- Conte C., Cipponeri E., Roden M., et al. Diabetes Mellitus, Energy Metabolism, and COVID-19. Endocr Rev. 2024;45(2):281–308. doi: 10.1210/endrev/bnad032.
- Cho J.H., Suh S. Glucocorticoid-Induced Hyperglycemia: A Neglected Problem. Endocrinol Metab (Seoul). 2024;39(2):222–38. doi: 10.3803/EnM.2024.1951.
